Kempner Capital Management Raised Merck & Co. (MRK) Holding By $2.51 Million; Biogen Idec (BIIB)’s Sentiment Is 1.17

Merck & Co., Inc. (NYSE:MRK) Logo

Kempner Capital Management Inc increased Merck & Co. Inc. (MRK) stake by 212.86% reported in 2017Q4 SEC filing. Kempner Capital Management Inc acquired 44,827 shares as Merck & Co. Inc. (MRK)’s stock declined 4.63%. The Kempner Capital Management Inc holds 65,886 shares with $3.71M value, up from 21,059 last quarter. Merck & Co. Inc. now has $158.52B valuation. The stock decreased 1.01% or $0.6 during the last trading session, reaching $58.87. About 13.10 million shares traded or 2.16% up from the average. Merck & Co., Inc. (NYSE:MRK) has declined 14.94% since May 1, 2017 and is downtrending. It has underperformed by 26.49% the S&P500.

Biogen Idec Inc (BIIB) investors sentiment increased to 1.17 in Q4 2017. It’s up 0.04, from 1.13 in 2017Q3. The ratio is more positive, as 410 investment managers started new or increased holdings, while 351 reduced and sold their holdings in Biogen Idec Inc. The investment managers in our database now hold: 180.65 million shares, down from 181.16 million shares in 2017Q3. Also, the number of investment managers holding Biogen Idec Inc in top ten holdings decreased from 28 to 22 for a decrease of 6. Sold All: 46 Reduced: 305 Increased: 305 New Position: 105.

Ratings analysis reveals 71% of Biogen’s analysts are positive. Out of 7 Wall Street analysts rating Biogen, 5 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $290.0 while the high is $386.0. The stock’s average target of $324.67 is 18.67% above today’s ($273.6) share price. BIIB was included in 7 notes of analysts from September 6, 2016. The stock has “Buy” rating by Citigroup on Tuesday, February 7. The firm has “Hold” rating given on Tuesday, September 6 by Jefferies. As per Tuesday, November 8, the company rating was initiated by Mizuho. The firm has “Hold” rating by Stifel Nicolaus given on Friday, December 9. The firm has “Overweight” rating given on Monday, November 7 by Piper Jaffray. The firm has “Outperform” rating by Leerink Swann given on Monday, November 7. As per Thursday, December 29, the company rating was maintained by Raymond James.

Sarissa Capital Management Lp holds 33.75% of its portfolio in Biogen Inc. for 413,858 shares. Healthinvest Partners Ab owns 8,400 shares or 5.65% of their US portfolio. Moreover, Terril Brothers Inc. has 5.65% invested in the company for 57,568 shares. The Massachusetts-based Tekla Capital Management Llc has invested 5.48% in the stock. Waverton Investment Management Ltd, a United Kingdom-based fund reported 290,016 shares.

Biogen Inc., a biopharmaceutical company, discovers, develops, makes, and delivers therapies for the treatment of neurological and autoimmune diseases worldwide. The company has market cap of $57.73 billion. The firm offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA to treat multiple sclerosis ; FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It has a 22.95 P/E ratio. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and other potential anti-CD20 therapies.

The stock decreased 1.16% or $3.2 during the last trading session, reaching $273.6. About 1.71M shares traded. Biogen Inc. (BIIB) has declined 3.66% since May 1, 2017 and is downtrending. It has underperformed by 15.21% the S&P500.

Since January 1, 0001, it had 1 buy, and 5 insider sales for $10.09 million activity.

Among 24 analysts covering Merck & Co. Inc. (NYSE:MRK), 21 have Buy rating, 0 Sell and 3 Hold. Therefore 88% are positive. Merck & Co. Inc. had 90 analyst reports since August 13, 2015 according to SRatingsIntel. The rating was maintained by UBS with “Buy” on Monday, July 31. Guggenheim upgraded Merck & Co., Inc. (NYSE:MRK) on Thursday, January 12 to “Buy” rating. Piper Jaffray maintained the shares of MRK in report on Friday, July 28 with “Buy” rating. Jefferies downgraded Merck & Co., Inc. (NYSE:MRK) on Monday, December 19 to “Underperform” rating. As per Monday, June 12, the company rating was maintained by BMO Capital Markets. The firm earned “Hold” rating on Tuesday, October 31 by Jefferies. The stock has “Sell” rating by Jefferies on Friday, August 18. The firm earned “Neutral” rating on Monday, May 9 by Credit Suisse. Piper Jaffray upgraded the stock to “Overweight” rating in Thursday, January 12 report. The firm has “Hold” rating by Jefferies given on Thursday, November 16.

Investors sentiment decreased to 0.94 in Q4 2017. Its down 0.12, from 1.06 in 2017Q3. It dived, as 94 investors sold MRK shares while 631 reduced holdings. 123 funds opened positions while 558 raised stakes. 1.93 billion shares or 1.34% less from 1.96 billion shares in 2017Q3 were reported. Loring Wolcott Coolidge Fiduciary Advsrs Llp Ma has 0.1% invested in Merck & Co., Inc. (NYSE:MRK). Sumitomo Mitsui Asset Management Limited accumulated 265,781 shares. Private Tru Na accumulated 58,227 shares. The Maine-based Hm Payson And Com has invested 0.86% in Merck & Co., Inc. (NYSE:MRK). Monroe National Bank Tru Mi reported 1,475 shares stake. Lee Danner And Bass has invested 0.6% in Merck & Co., Inc. (NYSE:MRK). Moreover, Rodgers Brothers has 0.87% invested in Merck & Co., Inc. (NYSE:MRK). Gemmer Asset Mngmt Limited owns 20,837 shares. Highbridge Capital Mgmt Ltd reported 327,576 shares stake. Conestoga Cap Advsrs Limited Com reported 6,900 shares stake. Regents Of The University Of California owns 21,600 shares. Elm Advisors Limited Liability Corp holds 0.44% or 10,571 shares in its portfolio. Thompson Invest Mngmt reported 0.21% in Merck & Co., Inc. (NYSE:MRK). Reynders Mcveigh Capital Mgmt Limited Liability Corporation holds 0.32% or 43,907 shares in its portfolio. James Invest Research holds 0.1% of its portfolio in Merck & Co., Inc. (NYSE:MRK) for 53,027 shares.

Merck & Co., Inc. (NYSE:MRK) Institutional Positions Chart